PL2354142T3 - Sposób wytwarzania stabilnej, amorficznej soli wapniowej kwasu (6S)-N(5)-metylo-5,6,7,8-tetrahydrofoliowego - Google Patents
Sposób wytwarzania stabilnej, amorficznej soli wapniowej kwasu (6S)-N(5)-metylo-5,6,7,8-tetrahydrofoliowegoInfo
- Publication number
- PL2354142T3 PL2354142T3 PL11003589T PL11003589T PL2354142T3 PL 2354142 T3 PL2354142 T3 PL 2354142T3 PL 11003589 T PL11003589 T PL 11003589T PL 11003589 T PL11003589 T PL 11003589T PL 2354142 T3 PL2354142 T3 PL 2354142T3
- Authority
- PL
- Poland
- Prior art keywords
- methyl
- tetrahydrofolic acid
- calcium salt
- aqueous solution
- acid
- Prior art date
Links
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 title abstract 6
- 159000000007 calcium salts Chemical class 0.000 title abstract 5
- 239000007864 aqueous solution Substances 0.000 abstract 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 abstract 2
- 239000001110 calcium chloride Substances 0.000 abstract 2
- 229910001628 calcium chloride Inorganic materials 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 abstract 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 210000004102 animal cell Anatomy 0.000 abstract 1
- JMNIIIQOMSQWJN-ZEXVLMPOSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound [Ca+2].C([C@@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1.C([C@@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1 JMNIIIQOMSQWJN-ZEXVLMPOSA-L 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 abstract 1
- 230000001035 methylating effect Effects 0.000 abstract 1
- 239000011541 reaction mixture Substances 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH00856/07A CH698729B1 (de) | 2007-05-30 | 2007-05-30 | Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure. |
| EP08748372A EP2162456B1 (de) | 2007-05-30 | 2008-05-29 | Stabile kristalline (6S) -N (5) -Methyl-5,6,7,8-tetrahydrofolsäure, deren Herstellung und Verwendung |
| EP11003589.6A EP2354142B1 (de) | 2007-05-30 | 2008-05-29 | Verfahren zur Herstellung des stabilen, amorphen Calciumsalzes von (6S)-N(5)-Methyl-5,6,7,8-tetrahydrofolsäure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2354142T3 true PL2354142T3 (pl) | 2014-01-31 |
Family
ID=38617354
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11003589T PL2354142T3 (pl) | 2007-05-30 | 2008-05-29 | Sposób wytwarzania stabilnej, amorficznej soli wapniowej kwasu (6S)-N(5)-metylo-5,6,7,8-tetrahydrofoliowego |
| PL08748372T PL2162456T3 (pl) | 2007-05-30 | 2008-05-29 | Stabilny, krystaliczny kwas (6S)-N(5)-metylo-5,6,7,8-tetrahydrofoliowy, sposób jego wytwarzania i zastosowanie |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08748372T PL2162456T3 (pl) | 2007-05-30 | 2008-05-29 | Stabilny, krystaliczny kwas (6S)-N(5)-metylo-5,6,7,8-tetrahydrofoliowy, sposób jego wytwarzania i zastosowanie |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8314102B2 (pl) |
| EP (2) | EP2354142B1 (pl) |
| JP (1) | JP5552422B2 (pl) |
| AT (1) | ATE515507T1 (pl) |
| AU (1) | AU2008255518C1 (pl) |
| CA (1) | CA2686519C (pl) |
| CH (1) | CH698729B1 (pl) |
| ES (2) | ES2430113T3 (pl) |
| PL (2) | PL2354142T3 (pl) |
| WO (1) | WO2008144953A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102516247A (zh) * | 2010-12-15 | 2012-06-27 | 连云港金康医药科技有限公司 | A型l-5-甲基四氢叶酸钙盐多晶型及其制备方法 |
| EP2502625A1 (en) * | 2011-03-21 | 2012-09-26 | GMT Fine Chemicals SA | Process for the preparation of crystalline levofolinic acid |
| CN104557937B (zh) * | 2012-01-20 | 2017-03-08 | 连云港金康和信药业有限公司 | (6s)‑5‑甲基四氢叶酸盐晶型及其制备方法 |
| CN102584826B (zh) * | 2012-01-20 | 2015-04-29 | 连云港金康医药科技有限公司 | (6s)-5-甲基四氢叶酸盐晶型及其制备方法 |
| BR112014017939A2 (pt) | 2012-01-20 | 2021-05-25 | Lianyungang Jinkang Hexin Pharmaceutical Co, Ltd. | Forma de cristal de sal de (6s)-5-metil-tetra-hidrofolato e método para preparação da mesma |
| CN103694239B (zh) * | 2012-09-27 | 2016-12-21 | 上海科胜药物研发有限公司 | 一种5‑甲基‑（6s）‑四氢叶酸晶型a及其制备方法 |
| EP2781214A1 (en) | 2013-03-22 | 2014-09-24 | Chemo Research, S.L. | Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca) |
| CN103214487A (zh) * | 2013-04-12 | 2013-07-24 | 张家港威胜生物医药有限公司 | 一种重要医药化工原料(6s)-5-甲基四氢叶酸盐的合成 |
| CA2974953A1 (en) | 2015-01-27 | 2016-08-04 | La Vita Compounding Pharmacy | Stable 5-methyltetrahydrofolate formulations to moderate methylenetetrahydrofolate reductase associated polymorphisms |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1572137A (en) * | 1977-02-22 | 1980-07-23 | Bioresearch Sas Del Dr Livio C | Stable compositions for therapeutic use based on d,1-5-methyltetrahydrofolic acid and its salts |
| DE3821875C1 (pl) * | 1988-06-29 | 1990-02-15 | Eprova Ag, Forschungsinstitut, Schaffhausen, Ch | |
| CH680731A5 (pl) * | 1990-04-12 | 1992-10-30 | Sapec Fine Chemicals | |
| CH681303A5 (pl) * | 1991-01-16 | 1993-02-26 | Eprova Ag | |
| DE4136921A1 (de) * | 1991-11-11 | 1993-05-13 | Knoll Ag | Verfahren zur trennung von 5-methyl-tetrahydrofolsaeure |
| CH686672A5 (de) * | 1992-12-01 | 1996-05-31 | Cerbios Pharma Sa | Verfahren zur Herstellung von (6S)-5,6,7,8-Tetrahydrofolsaeure. |
| JPH06271480A (ja) * | 1993-03-17 | 1994-09-27 | Sekisui Chem Co Ltd | 有機非線形光学材料の製造方法 |
| CH693905A5 (de) * | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
| JP2001072675A (ja) * | 1999-06-30 | 2001-03-21 | Takeda Chem Ind Ltd | ベンズイミダゾール化合物の結晶 |
| TWI377206B (en) * | 2005-04-06 | 2012-11-21 | Theravance Inc | Crystalline form of a quinolinone-carboxamide compound |
| JPWO2006121151A1 (ja) * | 2005-05-13 | 2008-12-18 | 第一三共株式会社 | １−メチルカルバペネム化合物の結晶 |
-
2007
- 2007-05-30 CH CH00856/07A patent/CH698729B1/de unknown
-
2008
- 2008-05-29 ES ES11003589T patent/ES2430113T3/es active Active
- 2008-05-29 WO PCT/CH2008/000242 patent/WO2008144953A1/de active Application Filing
- 2008-05-29 JP JP2010509650A patent/JP5552422B2/ja active Active
- 2008-05-29 ES ES08748372T patent/ES2366500T3/es active Active
- 2008-05-29 AT AT08748372T patent/ATE515507T1/de active
- 2008-05-29 EP EP11003589.6A patent/EP2354142B1/de active Active
- 2008-05-29 US US12/601,207 patent/US8314102B2/en active Active
- 2008-05-29 PL PL11003589T patent/PL2354142T3/pl unknown
- 2008-05-29 PL PL08748372T patent/PL2162456T3/pl unknown
- 2008-05-29 AU AU2008255518A patent/AU2008255518C1/en active Active
- 2008-05-29 CA CA2686519A patent/CA2686519C/en active Active
- 2008-05-29 EP EP08748372A patent/EP2162456B1/de active Active
-
2012
- 2012-08-14 US US13/585,627 patent/US8754212B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008255518A1 (en) | 2008-12-04 |
| ES2366500T3 (es) | 2011-10-20 |
| WO2008144953A1 (de) | 2008-12-04 |
| EP2162456A1 (de) | 2010-03-17 |
| EP2354142A1 (de) | 2011-08-10 |
| ES2430113T3 (es) | 2013-11-19 |
| JP5552422B2 (ja) | 2014-07-16 |
| PL2162456T3 (pl) | 2011-12-30 |
| US20130040956A1 (en) | 2013-02-14 |
| CA2686519C (en) | 2012-12-18 |
| CA2686519A1 (en) | 2008-12-04 |
| AU2008255518B2 (en) | 2011-08-25 |
| ATE515507T1 (de) | 2011-07-15 |
| US20100168117A1 (en) | 2010-07-01 |
| US8754212B2 (en) | 2014-06-17 |
| EP2354142B1 (de) | 2013-07-31 |
| JP2010528059A (ja) | 2010-08-19 |
| EP2162456B1 (de) | 2011-07-06 |
| AU2008255518C1 (en) | 2012-01-12 |
| CH698729B1 (de) | 2009-10-15 |
| US8314102B2 (en) | 2012-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2354142T3 (pl) | Sposób wytwarzania stabilnej, amorficznej soli wapniowej kwasu (6S)-N(5)-metylo-5,6,7,8-tetrahydrofoliowego | |
| TN2019000133A1 (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| PH12014502771A1 (en) | Nucleoside phosphoramidate prodrugs | |
| UA89123C2 (ru) | Производные пиримидина для лечения абнормального роста клеток | |
| NZ613219A (en) | Heterocyclic containing entities, compositions and methods | |
| PL159180B1 (pl) | [/Z/-2-/2-aminotiazolilo-4/ -4-karboksybuten-2-oiloamino]-3- cefemokarboksylowego-4 PL PL PL | |
| WO2009150137A3 (en) | Pyrazine derivatives as epithelial sodium channel blockers | |
| TW200517393A (en) | Processes for the preparation of benzoimidazole derivatives | |
| MX2011008839A (es) | Compuestos de 4-isopropilfenilglucitol como inhibidores de transportador de glucosa dependiente de sodio 1. | |
| MX2009005413A (es) | Formas cristalinas del acido zoledronico. | |
| AU2014311148B2 (en) | Vancomycin derivative, and preparation method and application thereof | |
| PL1751093T3 (pl) | Podstawione pochodne kwasu cykloheksylooctowego | |
| BR112014012942A2 (pt) | uso de derivados de aril para controle de ectoparasitas | |
| MX339302B (es) | 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina. | |
| MX2013002620A (es) | Novedosas n-hidroxi-benzamidas para el tratamiento del cancer. | |
| MX2021000683A (es) | Derivados de imidazo[1,2-b]piridazina como inhibidores de trk. | |
| CN103450202A (zh) | L-5-甲基四氢叶酸与有机碱加成盐的方法 | |
| UA106580C2 (uk) | Фармацевтично прийнятні солі тимодепресину і спосіб їх виробництва | |
| PL81921B1 (pl) | ||
| CN114230454B (zh) | 没食子酸类天然活性成分的钙配合物及其合成方法和应用 | |
| TW201720788A (zh) | 3-羥基異戊酸之一價陽離子鹽之結晶及該結晶之製造方法 | |
| RU2011136334A (ru) | Способ получения двухводного ацетата цинка | |
| CN104529807A (zh) | 一种n-氯乙酰-l-谷氨酰胺的制备方法 | |
| PL53371B1 (pl) | ||
| NZ730996A (en) | Carbidopa and l-dopa prodrugs and their use to treat parkinson’s disease |